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Autologous Stem Cell
Transplantation as Part
of First-Line Treatment
of Waldenstro¨m’s
Macroglobulinemia
In the August 2006 issue of BBMT, Anagnosto-
poulos and coworkers [1] reported superior outcome
of autologous (autoSCT, n 10) over allogeneic stem
cell transplantation (alloSCT, n  26) in 36 patients
with Waldenström’s macroglobulinemia (WM). Re-
ferring to data of our group, the authors discussed that
the results of autoSCT in WM might further be
improved by using this modality earlier during the
course of the disease. We would like to take the
opportunity to give an update of our approach, which
was originally published in 1999 [2].
WM patients were treated on subsequent prospec-
tive protocols aimed at investigating the feasibility and
efﬁcacy of autoSCT as part of ﬁrst-line treatment of
indolent lymphoma. The protocols, including the in-
formed consent forms, were approved by the respon-
sible institutional review board (Ethics Committee of
the University of Kiel). Patients gave written informed
consent using study-speciﬁc forms. Patients with
symptomatic disease were eligible if they were be-
tween 18 and 65 years old, had an adequate perfor-
mance status (Karnofsky 80%), and never received
WM-speciﬁc cytotoxic treatment. After an optional
initial cytoreduction with alkylators or ﬂudarabine,
patients were treated with 1-3 cycles of Dexa-BEAM
chemotherapy for stem cell mobilization and remis-
sion induction, followed by myeloablative therapy
with total body irradiation (TBI)/high-dose cyclo-
phosphamide and stem cell reinfusion. In the ﬁrst 5
patients, grafts were vigorously B cell-depleted by
immunomagnetic CD34 and/or negative B cell se-
lection [2].
Between March 1995 and September 2003, 12
consecutive patients fulﬁlling eligibility criteria were
included. Median age was 49 (39-61) years. Prior to
treatment, serum IgM levels were 46.7 (17.4-92.3)
g/L, and all patients had symptomatic disease because
of anemia, bulky lymphadenopathy, hyperviscosity,
and/or B symptoms. Four patients proceeded directly
to Dexa-BEAM mobilization, whereas the remainder
received 3-6 cycles of CHOP (4), R-CHOP (2),
chlorambucil (1), or ﬂudarabine (1) beforehand, re-
sulting in partial remission (5) or no response (3).
Mobilization failure did not occur. After myeloabla-
tive therapy and stem cell reinfusion (median CD34
cell number 5.3 (2.1-13.2) 106/kg), engraftment was
prompt, and toxic deaths did not occur. Although
autoSCT induced strong reduction or normalization
of serum IgM levels in all patients (5.4 [2.1-23.2] g/L
at 100 days posttransplant), immunoﬁxation remained
monoclonal in all but 2 patients, suggesting persis-
tence of residual disease. Disease progression was ob-
served in 6 patients, translating into a median progres-
sion-free survival of 69 months (Figure 1). Median
time to retreatment was 82 months, and all patients
are still alive after a median follow-up of 69 (25-123)
months after autoSCT.
In conclusion, these results show that ﬁrst-line
high-dose radiochemotherapy with autoSCT is
highly effective in patients with symptomatic WM.
Even though complete eradication of the disease
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does not seem to be possible with this approach, the
response rate is high, and long-term disease control
can be achieved in individual patients, favorably
comparing to what can be reached with intensive
purine analogue alkylator combination therapy [3].
It remains to be shown, however, what autoSCT can
add to the promising results obtained with ritux-
imab-containing ﬁrst-line regimens [4]. Accord-
ingly, autoSCT is currently considered as a recom-
mended option for salvage but not for ﬁrst-line
treatment of WM [5], and should be used in the
latter setting only within clinical trials.
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Figure 1. Progression-free survival from autoSCT (n  12; median
time to progression 69 months).
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